newsUnder a licensing and collaboration agreement, Partner Therapeutics will evaluate…
4 March 2021 | By Hannah Balfour (European Pharmaceutical Review)
Under a licensing and collaboration agreement, Partner Therapeutics will evaluate whether FX-06 could be used to treat multiple biothreats of interest to the US Government.